Eton Park Capital Management’s Biogen BIIB Stock Holding History

Eton Park Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-400,000	Closed	-$113M	–	29
2016 Q4	$113M	Buy	+400,000	New	+$119M	2.25%	14

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Eton Park Capital Management's BIIB Position: Q2 2017 in Review

Eton Park Capital Management sold out of Biogen (BIIB) in Q2 2017, closing a stake of 111,191 shares — an estimated $30.4M sold.

Eton Park Capital Management first reported a position in BIIB in Q3 2016 and held it in 3 quarters. The position peaked at $93M in Q4 2016. 992 funds tracked by Wall St. Rank hold BIIB as of Q2 2017.

Eton Park Capital Management reported no remaining Biogen position as of Q2 2017 after selling out during the quarter.
Eton Park Capital Management sold 111,191 Biogen shares in Q2 2017, an estimated $30.4M.
Eton Park Capital Management first reported a position in Biogen in Q3 2016 and held it in 3 quarters.
Eton Park Capital Management's Biogen position peaked at $93M in Q4 2016.
992 funds tracked by Wall St. Rank held Biogen as of Q2 2017.

Based on Eton Park Capital Management's 13F filing for Q2 2017.